The Role of Complement Pathway Inhibitors in the Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Credit(s)

1.0

AMA PRA Category 1 CreditTM

Overview

This CME activity is derived from content presented at the 2026 AANEM Annual Meeting in Orlando, Florida. The expert faculty, Drs. Jeffrey Allen, Marinos Dalakas, and Katherine Ruzhansky will first review the pathophysiology of chronic inflammatory demyelinating polyneuropathy as well as the current standards of care and unmet needs for patients with CIDP. Following, the faculty will examine the current clinical trial data for new and emerging complement inhibitor therapeutics for the long-term management of patients with CIDP. The faculty will then discuss best practices for applying complement inhibitor therapeutics for their potential role when individualizing treatment plans to improve outcomes in patients with CIDP. To conclude, the faculty will present a patient case highlighting best practices for the treatment and management of patients with chronic inflammatory demyelinating polyneuropathy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Examine the pathophysiology of CIDP and the current standards of care and unmet needs for patients with CIDP
  • Evaluate the current clinical trial data for new and emerging complement inhibitor therapeutics for the long-term management of patients with CIDP
  • Discuss best practices for applying complement inhibitor therapeutics for their potential role when individualizing treatment plans to improve outcomes in patients with CIDP

Pre-Test

Complete the pre-quiz poll to access the course episodes. 

Prequiz Podcast | AANEMCIDPpod

Course Faculty

Jeffrey Allen, MD, FAAN
Jeffrey Allen, MD, FAAN
Professor, Department of Neurology
Section of Neuromuscular Medicine
University of Minnesota
Minneapolis, MN
Marinos Dalakas, MD, PhD
Marinos Dalakas, MD, PhD
Professor of Neurology (Endowed Chair)
Director, Neuromuscular Division & Clinical Neuroimmunology
Thomas Jefferson University
Philadelphia, PA
Katherine Ruzhansky, MD, MS
Katherine Ruzhansky, MD, MS
Professor of Neurology
Director of the Neuromuscular Division
Director of the EMG Laboratory
Medical University of South Carolina
Charleston, SC

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty Relationship Identified With:
Jeffrey Allen, MD

 

Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Alnylam; Amgen Inc.; Annexon, Inc.; argenx; AstraZeneca; CSL Behring; Dianthus Therapeutics; Grifols; Immunovant; Johnson & Johnson; Sanofi; Takeda Pharmaceutical Company Limited
Marinos Dalakas, MD, PhD

 

Consultant/Advisor: Adicet Bio; Amgen Inc.; argenx; Grifols; Shoreline Biosciences, Inc.
Katherine Ruzhansky, MD

 

Consultant Advisor: Amgen; Kyverna Therapeutics, Inc; UCB

Grant/Research Support: COUR Pharmaceuticals; Immunovant, Inc.; Janssen Pharmaceuticals, Inc.; Paradromics

Timothy Hayes, MD, PhD; Kim Cheramie, PhD, MSN, RN, NPDA-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Sanofi.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com.

ACCREDITATION

Earn your Credits After Completing Podcast Episodes

Related Podcast Courses

np microphone 888718 0E193A 1
Neurology
Clinical Update on the Evolving Role of B-Cell Targeting Therapies to Improve Outcomes in ...
np microphone 888718 0E193A 1
Neurology
Beyond Symptom Control: Targeting BAFF/APRIL Pathways in Generalized Myasthenia Gravis
np microphone 888718 0E193A 1
Cardiology
Neurology
Clinical Updates for Gene Silencing, RNA Interference Therapies for Transthyretin Amyloid ...